These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25006968)

  • 1. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
    Garin Shkolnik T; Feuerman H; Didkovsky E; Kaplan I; Bergman R; Pavlovsky L; Hodak E
    JAMA Dermatol; 2014 Sep; 150(9):984-9. PubMed ID: 25006968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
    Faulkner MA; Burke RA
    Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
    Tompson DJ; Crean CS; Reeve R; Berry NS
    Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
    Splinter MY
    Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.
    Brickel N; Hewett K; Rayner K; McDonald S; De'Ath J; Daniluk J; Joshi K; Boll MC; Tiamkao S; Vorobyeva O; Cooper J
    Epilepsy Behav; 2020 Jan; 102():106580. PubMed ID: 31731109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.
    Gil-Nagel A; Brodie MJ; Leroy R; Cyr T; Hall S; Castiglia M; Twomey C; VanLandingham K
    Epilepsy Res; 2012 Nov; 102(1-2):117-21. PubMed ID: 22771137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.
    Yamada M; Welty TE
    Ann Pharmacother; 2012 Oct; 46(10):1358-67. PubMed ID: 22991134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retigabine: blue skin discoloration and retinal pigment abnormalities.
    Prescrire Int; 2013 Nov; 22(143):269. PubMed ID: 24427841
    [No Abstract]   [Full Text] [Related]  

  • 9. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate.
    Beacher NG; Brodie MJ; Goodall C
    BMC Oral Health; 2015 Oct; 15(1):122. PubMed ID: 26452759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezogabine treatment of childhood absence epilepsy.
    Vossler DG; Yilmaz U
    Epileptic Disord; 2014 Mar; 16(1):121-4. PubMed ID: 24659629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZOGABINE (POTIGA) MACULOPATHY.
    Zaugg BE; Bell JE; Taylor KY; Bernstein PS
    Retin Cases Brief Rep; 2017 Winter; 11(1):38-43. PubMed ID: 26909536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.
    Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S
    Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
    French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
    Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
    Lerche H; Daniluk J; Lotay N; DeRossett S; Edwards S; Brandt C
    Seizure; 2015 Aug; 30():93-100. PubMed ID: 26216692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.
    Biton V; Gil-Nagel A; Brodie MJ; Derossett SE; Nohria V
    Epilepsy Res; 2013 Nov; 107(1-2):138-45. PubMed ID: 24094693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.
    Brickel N; Gandhi P; VanLandingham K; Hammond J; DeRossett S
    Epilepsia; 2012 Apr; 53(4):606-12. PubMed ID: 22428574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
    Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
    Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiepileptic medication linked to blue discoloration of the skin and eyes.
    Clark S; Antell A; Kaufman K
    Ther Adv Drug Saf; 2015 Feb; 6(1):15-9. PubMed ID: 25642319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.